Hangzhou Tigermed Consulting Co Ltd (3347)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 20 Oct 2026
Key indicators
| Last close | HKD 40.46 |
|---|---|
| 52-week range | 27.99 – 56.74 |
| Return, 1 month / 3 months | −11.3% / +7.8% |
| Return, 1 year / 3 years | −5.9% / +0.5% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 51.7% |
| Worst drawdown (1 year) | -46.6% |
| Average daily value traded | 64.91M HKD |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hangzhou Tigermed Consulting is a contract research organisation that helps pharmaceutical and biotechnology companies develop new medicines. It provides clinical trial services, including trial design and management, data management, statistical analysis, regulatory affairs support and medical writing. Its customers are drug developers and medical device makers that outsource parts of their research work. The company is based in Hangzhou, China, and serves clients in China and other markets.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 3347, and the price on this page is in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hangzhou Tigermed Consulting Co Ltd (3347) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 40.46 on 20 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 635 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 5.9% and over the last three months it rose 7.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -2.2% | ||
| From 52-week high | -26.4% | ||
| Momentum | 70 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.8% | ||
| 6-month return | -5.6% | ||
| 12-month return, skipping the last month | 6.2% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 51.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.6% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 64.91M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −10.2% |
|---|---|
| 1 month | −11.3% |
| 3 months | +7.8% |
| 6 months | −5.6% |
| 1 year | −5.9% |
| 3 years | +0.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 42.53 / 41.38 |
|---|---|
| Golden / death cross (60 days) | Golden, 12 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jun 2026 | HKD 0.1447 |
| 12 Jun 2025 | HKD 0.3245 |
| 7 Jun 2024 | HKD 0.6237 |
| 29 May 2024 | HKD 0.5680 |
| 25 May 2023 | HKD 0.6156 |
| 24 May 2022 | HKD 0.5796 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.